Opinion: Listen: Two Alzheimer’s experts with opposing viewpoints on Aduhelm
This week’s “First Opinion Podcast” is a special two-part episode focusing on the controversial — some say inflammatory — FDA decision to approve aducanumab, an Alzheimer’s drug developed by Biogen that will be marketed as Aduhelm. In these two episodes, I talk with two Alzheimer’s experts with vastly different viewpoints on the news: Dennis Selkoe, a physician and scientist whose research is at the core of how Aduhelm works; and Jason Karlawish, an Alzheimer’s physician who does not believe the drug is ready to be approved.
